Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
Investing.com - BTIG raised its price target on Adeptus Biotechnologies Corp. (NASDAQ:ADPT) to $14.00 from $13.00 on Wednesday, while maintaining a Buy rating on the stock. The company, currently valued at $1.68 billion, has seen its shares surge 139.7% over the past year. According to InvestingPro analysis, the stock is trading above its Fair Value.
The price target increase follows Adeptus Biotechnologies’ strong second-quarter performance, which included beating earnings expectations and raising its guidance for the year. The company achieved adjusted EBITDA positivity in its core MRD (Minimal Residual Disease) business during Q2 2025, ahead of its previous plan to reach this milestone in the second half of 2025. With revenue growth forecast at 22% for FY2025, InvestingPro data reveals strong momentum in the company’s financial trajectory.
BTIG noted that Adeptus is experiencing multiple growth drivers simultaneously, with robust trends in its core MRD business. The company has also lowered its cash burn outlook, which further strengthens its financial position. InvestingPro data shows a healthy current ratio of 2.92, indicating strong liquidity, though the company reported an EBITDA of -$117.41M in the last twelve months.
Despite Adeptus Biotechnologies having already raised guidance twice this year, BTIG believes there is still potential for additional upside to the company’s 2025 forecast. The firm highlighted the strong growth being driven by Adeptus’ core MRD clinical testing business.
According to BTIG’s analysis, Adeptus shares currently trade at 5.1 times the firm’s 2027 revenue estimate of $310 million, which is in line with historical peers that typically trade between 3-7 times revenue.
In other recent news, Adaptive Biotechnologies reported its second-quarter 2025 financial results, which exceeded market expectations. The company achieved a revenue of $58.9 million, marking a 36% increase compared to the previous year. Additionally, Adaptive Biotechnologies reported an earnings per share (EPS) of -$0.17, which was better than the forecasted -$0.24. These results highlight the company’s stronger-than-expected performance in the quarter. The positive earnings announcement was met with investor optimism, as reflected in aftermarket trading. There have been no recent reports of mergers or acquisitions involving Adaptive Biotechnologies. Additionally, there were no analyst upgrades or downgrades reported in the recent period. These developments indicate a period of growth and stability for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.